Trial Profile
A Phase 2, Randomized, Placebo-controlled, Double-blind, Crossover Study of DS-8500a to Evaluate the Effects on Pancreatic Beta Cell Function in Japanese Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Firuglipel (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 07 Nov 2016 Status changed from active, no longer recruiting to completed.
- 16 May 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.